Stimusil, Inc
Co-Founder & President, StimuSIL, Inc.
pablo@stimusil.com · stimusil.com · stimufield.com · linkedin.com/in/micho
Based in Madrid / Berlin
Tech and product founder with 15+ years as CEO across three ventures, generating $50M+ in cumulative revenue and two successful exits. Since 2020, building StimuSIL into a hair-health medtech company with two certified devices on the market and a growing clinical evidence base. At ASLMS 2026 to present clinical data and open distribution and strategic partnerships for the StimuField Cap (consumer PEMF) and SAGA-001 (in-office laser + microneedling).
**Co-Founder & President, StimuSIL, Inc.** (2020–present)
Hair and scalp health medtech company co-founded with Ana Villalba. Two product lines, one consumer and one professional, both targeting androgenetic alopecia.
• StimuField Cap — wearable PEMF device for at-home use. CE and FCC certified. $1,249 MSRP. $1M+ in orders to date, sold in the US and EU with wholesale and distribution partners.
• SAGA-001 — precision in-office system combining low-level laser therapy delivered through transparent microneedles. First randomized controlled pilot trial completed in Turkey in September 2024.
## ASLMS 2026 (Savannah, May 7–10)
• Three abstracts accepted, including two oral presentations.
• Lead abstract: *Safety and Efficacy of an Intradermal Laser Delivered via Transparent Microneedles for Androgenetic Alopecia: A Randomized Controlled Pilot Study* (co-authored with Mehmet A. Kosoglu, PhD).
• Exhibiting both StimuField Cap and SAGA-001 on-site; open for distributor and strategic partner meetings.
## Education
• Aerospace Engineering, École Polytechnique (France)
• Aerospace Engineering, Universidad Politécnica de Madrid (Spain)
## Selected recognition and activities
• Two successful startup exits (Redbooth, 8fit).
• Mentor, Founder Institute Madrid.
• Regular speaker on product, entrepreneurship, and biotech (Startup Grind Barcelona, BioEmprendedores podcast, actúaUPM).
## Languages
Spanish (native), English (fluent, business and clinical).
Friday, May 8, 2026
8:04 AM - 8:07 AM EDT